Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host disease rates.
Stem cell transplants for acute leukemia using pooled, non-human leukocyte antigen (HLA)-matched cord blood led to near-perfect engraftment and no severe graft-versus-host disease (GVHD) in a small ...
Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
Jakafi XR and the Jakafi XR logo are trademarks of Incyte.
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have failed to respond to systemic corticosteroids following a ...
Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results